First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Impact ledger

    Fulcrum Therapeutics, Inc. (FULC): the developments shaping its investment case

    Follow the evidence affecting Fulcrum Therapeutics, Inc.'s valuation assumptions, demand outlook. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.

    Research Fulcrum Therapeutics, Inc. · $399/mo

    Test assumptions, examine opportunities, and save your research.

    Material developments

    2026-08-17 · 2 reports
    Fulcrum Therapeutics, Inc. to Acquire Slate Medicines, Inc.
    Channel: Direct impact from acquisition terms, strategic shift, and operational integration. All-stock deal implies dilution for existing shareholders but also preserves cash.
    mixed· 1-5y
    2026-08-17 · 2 reports
    Fulcrum Therapeutics, Inc. Follow-On — $245M
    Channel: Direct capital infusion and share dilution. The financing provides capital for the merger and future operations but also increases the share count, which can dilute existing shareholders.
    mixed· 1-3m
    2026-09-02
    Fulcrum Therapeutics, Inc. Files S-4 Registration Statement for Merger
    Channel: Regulatory filing for a business combination, indicating progress towards merger completion. The S-4 details the terms, target company, and post-merger governance.
    mixed· 3-12m

    Evidence affecting valuation assumptions

    Each entry names the assumption the evidence touches and how the evidence reads. Direction describes the business mechanism, not a stock-price conclusion.

    DateAssumptionDirectionInterpretation
    2026-08-17share_countBullishThe merger involves issuing shares to Slate stockholders and investors in a concurrent investment, significantly increasing the total shares outstanding.
    2026-08-17multipleBearishIncremental float typically compresses near-term multiple absent revenue acceleration.
    2026-08-17share_countBullishPrimary equity issuance increases diluted share count.
    2026-08-17share_countBullishStock component of consideration dilutes existing acquirer holders.
    2026-08-17net_debtBullishCash component of consideration is typically debt-funded, raising net debt.
    2026-08-17revenueBullishAcquisition adds target revenue to acquirer P&L on close.

    Event impact log

    5 events mapped to FULC since 2026-08-17. Evidence through 2026-09-02.

    DateEventChannelDirectionHorizonImpact
    2026-09-02Fulcrum Therapeutics, Inc. Files S-4 Registration Statement for MergerRegulatory filing for a business combination, indicating progress towards merger completion. The S-4 details the terms, target company, and post-merger governance.mixed3-12m0.60
    2026-08-17Fulcrum Therapeutics, Inc. to Acquire Slate Medicines, Inc.Direct impact from acquisition terms, strategic shift, and operational integration. All-stock deal implies dilution for existing shareholders but also preserves cash.mixed1-5y0.80
    2026-08-17Fulcrum Therapeutics, Inc. Follow-On — $245MDirect capital infusion and share dilution. The financing provides capital for the merger and future operations but also increases the share count, which can dilute existing shareholders.mixed1-3m0.80
    2026-08-17Fulcrum Therapeutics, Inc. to Merge with Slate Medicines, Inc.Direct merger terms, equity dilution, cash dividend, strategic shift, and new pipeline integration.mixed1-3m0.90
    2026-08-17Slate Medicines, Inc. Follow-On — $245MDilution from new share issuance, but also strengthened balance sheet for R&D and operations post-merger.mixed1-3m0.70

    Continue this research

    Build your Fulcrum Therapeutics, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.

    This ledger is regenerated from Market Ontology's public event pipeline. View the FULC entity page →

    Research Fulcrum Therapeutics, Inc. · $399/mo